biotech investing news from FierceBiotech
News
Roche: Economic crisis won't stop Genentech bid
Roche is reassuring everyone that despite all the market turmoil that has occurred worldwide in recent weeks, it's still on track to raise the Read more...
In rocky market, Fluidigm withdraws IPO
Fluidigm was prepared to boldly go where few have gone this year: the public markets. The South San Francisco based company, which develops, manufactures and markets microfluidics products,... Read more...
Economic crisis rips biotech's bargaining position
Up to now it's been a sellers market for European biotechs when it comes to making deals with pharma organizations out to the beef up their pipelines. Now the Financial Times says that the credit... Read more...
Fund manager: Pharmas must buy biotechs--or die
Some of the smartest money on Wall Street is betting that the hot pace of biotech buyouts still has a long way to run. Andrej Hrovat, who runs the RH&Partner Global Life Science Fund, says... Read more...
Economy catches up with biotech investing
Early in 2008, life science investment was on a roll. It seemed as though the industry wouldn't be bothered by many problems affecting the rest of the economy, and that it was a safe haven compared... Read more...
In tough market, biotech shines
Wall Street has been in a tough spot these last few months, with the S&P 500 losing 9.5 percent over the course of June and July. But the biotech industry has Read more...
E&Y forecasts new wave of biotech deal-making
Ernst & Young took a look into biotechnology's crystal ball and came up with a Read more...
European investors sour on biotech market
There's a loud drumbeat of warnings coming from Europe over the sour state of biotech investing. Zhining Xu, an analyst at Seymour Pierce, tells the Financial Times that 2007 was a "Read more...
In VC market, life sciences dominate
In the first quarter of this year, venture capital investment dipped 5 percent to $7.1B, signaling that the current economic slump could have an impact on venture financing. However, there was still... Read more...
Biotech sees big money from corporate players
Corporations see some big advantages in investing in their own fields. A new report from the National Venture Capital Association finds that corporations funneled $1.3 billion in venture funds to... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
